论文部分内容阅读
为研究原癌基因c－erbB2、抑癌基因P53与卵巢上皮癌的关系，本文用免疫组化技术检测10例良性卵巢上皮肿瘤，25例交界性卵巢上皮肿瘤及72例卵巢上皮癌中c－erbB2、P53表达情况。结果表明：c－erbB2、P53在良性、交界性、恶性肿瘤中阳性表达有显著性差异（P＜0．01）。在病理组织类型中c－efbB2表达无明显差异（P＞0．05），而P53蛋白表达有明显差异（P＜0．05）。随诊资料中发现死亡病人c－erbB2、P53蛋白表达阳性率为65．38％和84．62％。提示，卵巢癌的发生发展与原癌基因c－erbB2的激活、抑癌基因P53失活有关，P53蛋白过度表达与卵巢癌恶性生物学行为有关，有可能作为临床预后指标之一。
To investigate the relationship between the oncogene c-erbB2 and tumor suppressor gene P53 and epithelial ovarian cancer, 10 cases of benign ovarian epithelial tumors, 25 borderline ovarian epithelial tumors, and 72 cases of epithelial ovarian cancer were examined by immunohistochemistry. erbB2, P53 expression. The results showed that there were significant differences in the positive expression of c-erbB2 and P53 in benign, borderline, and malignant tumors (P<0.01). There was no significant difference in the expression of c-efbB2 in pathological tissue types (P>0.05), but there was a significant difference in the expression of P53 protein (P<0.05). The follow-up data found that the positive rate of c-erbB2 and P53 protein expression in dead patients was 65.38% and 84.62%. It is suggested that the occurrence and development of ovarian cancer is associated with the activation of the oncogene c-erbB2 and the inactivation of tumor suppressor gene P53. The overexpression of P53 protein is associated with the malignant biological behavior of ovarian cancer, which may be one of the clinical prognostic indicators.